WebbSeelos Therapeutics Inc ( NASDAQ:SEEL) CEO Dr. Raj Mehra tells Proactive Investors the company has acquired an exclusive license to the rights to a potential Parkinson’s disease therapy created by researchers at the University of California, Los Angeles. Mehra said the therapy, known as SLS-007, may slow the progression of Parkinson's disease. Webb11 apr. 2024 · New York — Seelos Therapeutics, Inc. (Nasdaq: SEEL) (“Seelos”), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced it has dosed the first patient in an Expanded Access Program (EAP) for patients with ALS who do not qualify for existing …

Seelos Therapeutics - SEEL Stock Forecast, Price & News

Webbseelostherapeutics.com WebbSeelos Therapeutics is a biopharmaceutical company based in New York City. Founded in 2016, the company is now developing a ketamine spray to treat acute suicidal ideation, Major Depressive Disorder, and Post-Traumatic Stress Disorder. The single-use, bi-dose intranasal spray is currently the company’s only psychedelic-related product. qual light sports lighting

Raj Mehra Is The Founder of Seelos Therapeutics, Inc.

Webb31 mars 2024 · Dr. Raj Mehra J.D., Ph.D. Net Worth The estimated Net Worth of Raj Mehra is at least Seelos Therapeutics stock worth over $2,264,267 and over the last 3 years he … Webb29 mars 2024 · Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. WebbNew York, NY 10019 (617) 308-4306 [email protected] SOURCE Seelos Therapeutics, Inc. 11/23/2024 8:00:00 AM qualley and davidson